Functional response, in T2 severe asthmatic patients, treated with mepolizumab for 2 years

The increase in FEV1 observed in this cohort of patients shows that functional response is already detectable in the first two months of treatment. These clinical and functional improvements were sustained over two years of biologic therapy, even as pharmacologic treatment-particularly systemic corticosteroids-was progressively reduced.